|
Treatment must be initiated by a doctor with experience in diagnosing and treating Alzheimer's dementia, and
only when the guardian can periodically check the patient's medication intake. Diagnosis should be made according to current guidelines. Periodically reevaluate the clinical benefit of this drug and
the patient's tolerability (resistance to the drug). This drug can be taken with or without food.
1. Adult
dose increase: The maximum daily dose is 20 mg, and to minimize the risk of adverse reactions, increase by 5 mg per week for the first 3 weeks as follows
to reach the maintenance dose.
1st week (Day 1-7): Administer 5 mg per day for 7 days.
Second week (8th to 14th): Administer 10mg (5mg twice a day) per day for 7 days.
3rd week (15th to 21st): 15mg per day (10mg in the morning, 5mg in the evening) is administered for 7 days.
From the 4th week: Administer 20mg per day (10mg twice a day).
Maintenance dose: The recommended maintenance dose is 20 mg per day (10 mg twice a day).
2.
Based on geriatric clinical data, the recommended dose for elderly patients over 65 years of age is 20 mg per day (10 mg twice a day).
3. Patients with renal impairment (kidney failure)
No dose adjustment is required in patients with mild (mild symptom) renal impairment (renal impairment) (creatinine clearance: 50-80 mL/min). In patients with moderate
renal impairment (renal impairment) (creatinine clearance of 30-50 mL/min), the daily dose should be reduced to 10 mg. If tolerability (tolerance to the drug) is good after at least 7 days
after administration, the dose can be increased up to 20 mg per day according to the standard dose increase method.
In patients with severe (severe symptoms) renal impairment (renal impairment) (creatinine clearance of 5 to 30 mL/min), the daily dose should be reduced to 10 mg.
4. Patients
with hepatic impairment No dose adjustment is required in patients with mild (mild symptoms) or moderate hepatic impairment (Child-Pugh A, Child-Pugh B).
Since there are no data on the use of memantine in patients with severe (severe symptoms) hepatic impairment, it is not recommended to administer this drug.
|
